ImmuCell Statistics
Total Valuation
ImmuCell has a market cap or net worth of $68.68 million. The enterprise value is $65.73 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmuCell has 9.04 million shares outstanding. The number of shares has increased by 9.37% in one year.
| Current Share Class | 9.04M |
| Shares Outstanding | 9.04M |
| Shares Change (YoY) | +9.37% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 27.96% |
| Owned by Institutions (%) | 13.39% |
| Float | 6.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.90 |
| Forward PS | n/a |
| PB Ratio | 1.90 |
| P/TBV Ratio | 1.93 |
| P/FCF Ratio | 70.57 |
| P/OCF Ratio | 36.79 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 22.82, with an EV/FCF ratio of 83.33.
| EV / Earnings | n/a |
| EV / Sales | 2.41 |
| EV / EBITDA | 22.82 |
| EV / EBIT | 356.23 |
| EV / FCF | 83.33 |
Financial Position
The company has a current ratio of 4.12, with a Debt / Equity ratio of 0.51.
| Current Ratio | 4.12 |
| Quick Ratio | 2.07 |
| Debt / Equity | 0.51 |
| Debt / EBITDA | 4.34 |
| Debt / FCF | 18.58 |
| Interest Coverage | 0.34 |
Financial Efficiency
Return on equity (ROE) is -1.01% and return on invested capital (ROIC) is 0.27%.
| Return on Equity (ROE) | -1.01% |
| Return on Assets (ROA) | 0.26% |
| Return on Invested Capital (ROIC) | 0.27% |
| Return on Capital Employed (ROCE) | 0.44% |
| Revenue Per Employee | $364,037 |
| Profits Per Employee | -$3,624 |
| Employee Count | 75 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 2.47 |
Taxes
In the past 12 months, ImmuCell has paid $10,620 in taxes.
| Income Tax | 10,620 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +78.82% in the last 52 weeks. The beta is 0.31, so ImmuCell's price volatility has been lower than the market average.
| Beta (5Y) | 0.31 |
| 52-Week Price Change | +78.82% |
| 50-Day Moving Average | 5.80 |
| 200-Day Moving Average | 4.79 |
| Relative Strength Index (RSI) | 72.85 |
| Average Volume (20 Days) | 27,446 |
Short Selling Information
The latest short interest is 5,720, so 0.06% of the outstanding shares have been sold short.
| Short Interest | 5,720 |
| Short Previous Month | 11,645 |
| Short % of Shares Out | 0.06% |
| Short % of Float | 0.10% |
| Short Ratio (days to cover) | 0.24 |
Income Statement
In the last 12 months, ImmuCell had revenue of $27.30 million and -$271,778 in losses. Loss per share was -$0.03.
| Revenue | 27.30M |
| Gross Profit | 9.41M |
| Operating Income | 184,517 |
| Pretax Income | -3.89M |
| Net Income | -271,778 |
| EBITDA | 2.88M |
| EBIT | 184,517 |
| Loss Per Share | -$0.03 |
Full Income StatementBalance Sheet
The company has $4.60 million in cash and $14.66 million in debt, giving a net cash position of -$10.06 million or -$1.11 per share.
| Cash & Cash Equivalents | 4.60M |
| Total Debt | 14.66M |
| Net Cash | -10.06M |
| Net Cash Per Share | -$1.11 |
| Equity (Book Value) | 28.99M |
| Book Value Per Share | 3.23 |
| Working Capital | 12.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $1.51 million and capital expenditures -$724,419, giving a free cash flow of $788,815.
| Operating Cash Flow | 1.51M |
| Capital Expenditures | -724,419 |
| Free Cash Flow | 788,815 |
| FCF Per Share | $0.09 |
Full Cash Flow StatementMargins
Gross margin is 34.45%, with operating and profit margins of 0.68% and -1.00%.
| Gross Margin | 34.45% |
| Operating Margin | 0.68% |
| Pretax Margin | -0.96% |
| Profit Margin | -1.00% |
| EBITDA Margin | 10.55% |
| EBIT Margin | 0.68% |
| FCF Margin | 2.89% |
Dividends & Yields
ImmuCell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.37% |
| Shareholder Yield | -9.37% |
| Earnings Yield | -0.49% |
| FCF Yield | 1.42% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmuCell has an Altman Z-Score of 1.86 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.86 |
| Piotroski F-Score | 7 |